Profile data is unavailable for this security.
About the company
Harbin Pharmaceutical Group Co Ltd is a China-based company mainly engaged in the research and development, manufacturing, wholesale and retail of pharmaceutical. The Company is mainly engaged in two businesses. The pharmaceutical industry business is mainly engaged in the research, development and manufacturing of chemical raw materials, chemical preparations, biological preparations, traditional Chinese medicine and health care products. The pharmaceutical commercial business is mainly engaged in pharmaceutical commercial wholesale business and pharmaceutical commercial retail business. The Company's products mainly include zinc gluconate oral solution, calcium iron zinc oral solution, compound calcium gluconate oral solution, amoxicillin capsules and Shuanghuanglian oral solution. The Company's products are mainly used in digestive, respiratory, anti-infectious, cardiovascular and cerebrovascular and anti-tumor treatment fields.
- Revenue in CNY (TTM)15.67bn
- Net income in CNY449.71m
- Incorporated1991
- Employees9.85k
- LocationHarbin Pharmaceutical Group Co LtdNo. 7 Qunli Avenue, Daoli DistrictHAERBIN 150070ChinaCHN
- Phone+86 45 151870077
- Fax+86 45 151870077
- Websitehttps://www.hayao.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jianmin Pharmaceutical Group Co Ltd | 4.17bn | 521.42m | 7.28bn | 2.50k | 13.93 | 3.09 | -- | 1.75 | 3.41 | 3.41 | 27.26 | 15.35 | 1.04 | 5.81 | 4.34 | 1,669,960.00 | 13.09 | 10.87 | 23.66 | 19.11 | 43.70 | 43.04 | 12.56 | 9.32 | 1.26 | -- | 0.1891 | 37.15 | 15.72 | 14.28 | 27.78 | 45.05 | 8.77 | 43.10 |
| Jinyu Bio-Technology Co Ltd | 1.58bn | 282.51m | 7.33bn | 1.65k | 25.27 | 1.30 | -- | 4.63 | 0.2588 | 0.2588 | 1.44 | 5.05 | 0.2365 | 2.06 | 1.98 | 956,543.20 | 4.09 | 4.82 | 4.79 | 5.68 | 57.97 | 58.78 | 17.28 | 19.91 | 3.33 | -- | 0.0043 | 36.41 | 4.55 | -3.37 | 34.63 | -17.77 | -12.92 | -25.56 |
| Guangxi Wuzhou Zhongheng Group Co Ltd | 3.23bn | 156.14m | 7.49bn | 2.89k | 47.78 | 1.14 | -- | 2.32 | 0.0454 | 0.0454 | 0.9413 | 1.91 | 0.2766 | 1.96 | 3.41 | 1,120,149.00 | 0.9542 | 2.26 | 1.51 | 3.38 | 53.66 | 72.05 | 3.45 | 7.27 | 2.38 | -- | 0.1795 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| North China Pharmaceutical Co Ltd | 10.02bn | 17.62m | 7.64bn | 10.16k | 433.30 | 1.43 | -- | 0.7622 | 0.0103 | 0.0103 | 5.84 | 3.11 | 0.4693 | 2.71 | 4.31 | 986,082.90 | 0.3543 | -0.2978 | 0.8122 | -0.7042 | 30.26 | 35.73 | 0.755 | -0.5985 | 0.5425 | 1.43 | 0.6473 | -- | -3.62 | 1.89 | 100.71 | -49.62 | 4.22 | -19.73 |
| Harbin Pharmaceutical Group Co., Ltd. | 15.67bn | 449.71m | 7.86bn | 9.85k | 17.08 | 1.60 | -- | 0.5015 | 0.1827 | 0.1827 | 6.34 | 1.95 | 1.13 | 6.35 | 3.46 | 1,590,093.00 | 3.79 | 0.7414 | 10.20 | 1.89 | 26.30 | 23.87 | 3.35 | 0.7294 | 1.06 | 40.41 | 0.393 | 0.00 | 11.93 | 7.41 | -14.88 | 2.69 | -5.38 | -- |
| Nanjing Vazyme Biotech Co Ltd | 1.29bn | -15.12m | 7.86bn | 2.70k | -- | 1.95 | -- | 6.12 | -0.0368 | -0.0368 | 3.27 | 10.07 | 0.2191 | 0.9761 | 2.85 | 476,061.10 | -0.286 | 13.16 | -0.3724 | 15.92 | 71.31 | 70.50 | -1.31 | 23.92 | 2.97 | -- | 0.2154 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Youcare Pharmaceutical Group Co Ltd | 4.04bn | 168.83m | 8.40bn | 3.18k | 49.69 | 2.30 | -- | 2.08 | 0.3757 | 0.3757 | 8.97 | 8.13 | 0.6518 | 2.07 | 4.09 | 1,269,471.00 | 2.76 | 7.11 | 4.15 | 11.65 | 59.54 | 64.14 | 4.24 | 8.07 | 1.42 | -- | 0.2079 | 60.95 | -7.61 | 1.05 | -44.84 | -7.16 | 23.40 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023 | 34.96m | 1.39% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 7.27m | 0.29% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 4.10m | 0.16% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 3.45m | 0.14% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 31 Dec 2023 | 3.26m | 0.13% |
| Gfund Management Co., Ltd.as of 31 Dec 2023 | 1.19m | 0.05% |
| Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 557.60k | 0.02% |
| Guotai Asset Management Co., Ltd.as of 31 Dec 2023 | 542.80k | 0.02% |
| China Universal Asset Management Co., Ltd.as of 31 Dec 2023 | 473.30k | 0.02% |
| Harvest Fund Management Co., Ltd.as of 31 Dec 2023 | 311.50k | 0.01% |
